Biosimilars Canada today welcomed the release of the details of the Government of Quebec’s biosimilar switching policy, which will increase the use of biosimilar medicines under the Public Prescription Drug Insurance Plan and generate significant savings for the province.
The following are news releases and statements issued by Biosimilars Canada. News stories about biosimilars that may be of interest to readers are available here.
Toronto, May 18, 2021 – Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian Dubé for announcing the province’s intention to implement a biosimilar switching policy under its public prescription drug insurance plan.The expanded use of...
Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of New Brunswick for implementing a biosimilar “switching” or transitioning policy to expand the use of biosimilar medicines under the province’s public drug plans.
Biosimilars Canada today congratulated British Columbia and Health Minister Adrian Dix on the expansion of the province’s biosimilar switching program to include Humira adalimumab and a new indication for Enbrel etanercept.
Biosimilars Canada is pleased to announce the unanimous re-election of Mr. Michel Robidoux, President and General Manager of Sandoz Canada, as Chair of the Biosimilars Canada Board. Mr. Mike Woolcock, a Senior Vice President at Apobiologix, has been unanimously re-elected as Vice-Chair of the Biosimilars Canada Board.
CGPA / Biosimilars Canada Statement: COVID-19 and the Supply of Generic and Biosimilar Prescription Medicines to Canada’s Hospitals
Member companies of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working with our partners in government and the pharmaceutical supply chain to mitigate shortages of medicines used in Canada’s hospitals due to increases in demand resulting from the COVID-19 outbreak.